Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Unicon Bioengineering is a Chinese biotechnology company specializing in the development and manufacture of high-performance cell culture media for the biopharmaceutical industry. The company offers a diverse portfolio of serum-free, chemically defined, and animal-derived component-free media designed for various cell lines, including CHO, HEK293, Vero, and insect cells. These products support the large-scale production of monoclonal antibodies, recombinant proteins, vaccines, and cell therapies. Beyond off-the-shelf products, Unicon provides customized media formulation services and bioprocess optimization to enhance production efficiency for its clients. Headquartered in Huzhou, Zhejiang, the company operates state-of-the-art GMP-compliant manufacturing facilities to ensure high quality and consistency.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Unicon Bioengineering.